NBTX News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

NB

Mkt Cap

$1.09B

Volume

76.63K

Loading chart

NB

NBTXNanobiotix S.A. American Depositary Shares

NBTX

Pay with—

Available Balance0.00

NB

Mkt Cap

$1.13B

Volume

76.62K

Next Earnings

N/A

Chart Earnings News About Insider Filings

Head and Neck Squamous Cell Carcinoma (HNSCC) - Market Insights, Epidemiology, and Market Forecast - 2036 | Set to Reach $2.56 Billion as HPV-Targeted Vaccines Reshape CareThe HNSCC market is projected to grow from $850 million in 2025 to $2.56 billion by 2036 (10.5% CAGR), driven by HPV-targeted vaccines, checkpoint inhibitors, and biomarker-led patient selection. The US will remain the largest market at $2.082 billion. Key therapies include KEYTRUDA and OPDIVO, with emerging candidates like petosemtamab and amivantamab showing promise in clinical development.GlobeNewswire Inc. · Sep 30, 2026

NANOBIOTIX annonce le règlement-livraison de son offre globaleNANOBIOTIX completed a global offering raising approximately $100 million in gross proceeds through the full exercise of the underwriters' over-allotment option. The offering included 2,218,467 ordinary shares and 345,099 pre-funded warrants at €33.60 per share. The company plans to allocate proceeds toward JNJ-1900 development (less than 10%), Nanoprimer and other platforms (50-60%), and general corporate needs (30-40%), with sufficient runway through 2029.GlobeNewswire Inc. · May 26, 2026

NANOBIOTIX Announces Closing of Global OfferingNanobiotix, a late-clinical stage biotechnology company, announced the closing of its global offering on May 26, 2026, raising approximately $100 million in gross proceeds following the full exercise of underwriters' over-allotment option. The company issued 2,218,467 ordinary shares and 345,099 pre-funded warrants at €33.60 per share. Net proceeds will be allocated toward advancing the Nanoprimer platform (50-60%), general corporate purposes (30-40%), and JNJ-1900 development (less than 10%). The company expects its financial resources to support operations into 2029.GlobeNewswire Inc. · May 26, 2026

Nanobiotix Announces Pricing of Oversubscribed €85m Global OfferingNanobiotix, a late-clinical stage biotechnology company, announced the pricing of its global follow-on offering consisting of 225,373 ADSs in the U.S. at $38.98 per share and 1,959,289 ordinary shares plus 345,099 pre-funded warrants in Europe at €33.60 per share. The offering is expected to raise approximately €85.0 million in gross proceeds. The company plans to use net proceeds for advancing its Nanoprimer platform (50-60%), general corporate purposes (30-40%), and supporting JNJ-1900 development (less than 10%). The offering is supported by existing shareholders including Qatar Holding LLC and Invus.GlobeNewswire Inc. · May 21, 2026

Nanobiotix Announces Temporary Trading Halt of Its Ordinary Shares on Euronext ParisNanobiotix announced a temporary trading halt on Euronext Paris effective May 21, 2026, to facilitate the pricing and allocation confirmation of its global follow-on offering. The offering consists of a U.S. public offering of American Depositary Shares and an international offering of ordinary shares and pre-funded warrants to qualified investors in Europe and other countries. Trading is expected to resume at approximately 3:30 p.m. Paris time.GlobeNewswire Inc. · May 21, 2026

Nanobiotix Announces Launch of Global Follow-On OfferingNanobiotix, a late-clinical stage biotechnology company, announced the launch of an approximately €75 million (~$87 million) global follow-on offering consisting of American Depositary Shares and Ordinary Shares in the U.S. and Europe. The company plans to allocate proceeds toward advancing its Nanoprimer platform (50-60%), general corporate purposes (30-40%), and JNJ-1900 development (less than 10%). The offering is expected to price before U.S. market open on May 21, 2026.GlobeNewswire Inc. · May 20, 2026

Nanobiotix annonce le lancement d’une offre globaleNanobiotix announced a global follow-on offering of approximately €75 million (~$87 million USD) comprising an ADS offering in the US and an offering of ordinary shares and pre-funded warrants to qualified investors in Europe and other countries. The proceeds will be allocated primarily to advancing the Nanoprimer platform (50-60%), general corporate needs (30-40%), and JNJ-1900 development (less than 10%). The offering is being coordinated by Jefferies, TD Cowen, and Stifel.GlobeNewswire Inc. · May 20, 2026

Nanobiotix Announces Launch of Global Follow-On OfferingNanobiotix, a late-clinical stage biotechnology company, announced the launch of an approximately €75 million (~$87 million) global follow-on offering consisting of American Depositary Shares and Ordinary Shares in the U.S. and Europe. The offering will be priced before U.S. market open on May 21, 2026, with net proceeds allocated toward advancing the Nanoprimer platform (50-60%), general corporate purposes (30-40%), and JNJ-1900 development (less than 10%). Jefferies, TD Cowen, and Stifel are acting as global coordinators.GlobeNewswire Inc. · May 20, 2026

NANOBIOTIX ANNONCE LA PRÉSENTATION DE DONNÉES DE LA PREMIÉRE PARTIE DE L’ÉTUDE CLINIQUE RANDOMISÉE DE PHASE 2 EVALUANT JNJ-1900 (NBTXR3) DANS LES CANCERS DU POUMON DE STADE 3 INOPÉRABLENanobiotix announced early results from the Phase 2 CONVERGE study evaluating JNJ-1900 (NBTXR3), a nanoradioenhancer developed in collaboration with Johnson & Johnson, in patients with stage 3 inoperable non-small cell lung cancer. The study showed promising efficacy with an 85.7% overall response rate and 57.1% complete response rate in 7 patients who completed treatment, compared to less than 5% complete response rates with current standard of care.GlobeNewswire Inc. · May 17, 2026

Nanobiotix Announces Presentation of Part 1 Data From a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung CancerNanobiotix announced promising Part 1 data from the CONVERGE Phase 2 study evaluating JNJ-1900 (NBTXR3), a nanoradioenhancer, in stage 3 inoperable non-small cell lung cancer. Results showed an 85.7% overall response rate and 57.1% complete response rate in 7 patients receiving the treatment combined with concurrent chemoradiotherapy and durvalumab, significantly exceeding the <5% complete response rate of standard care.GlobeNewswire Inc. · May 17, 2026

to start trading

NB

NBTXNanobiotix S.A. American Depositary Shares

NBTX

Pay with—

Available Balance0.00

Your PositionYou don't own any NBTX yet.

Related Tickers

Earnings